A study to test a medicine (fitusiran) for preventing bleeds in people with severe hemophilia who previously received preventive treatment with emicizumab

2022-502414-84-00 Protocol SFY17741 Human pharmacology (Phase I) - Other Ended

End 24 Sep 2024 · Status Ended · 2 EU/EEA countries · 5 sites · Protocol SFY17741

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 26
Countries 2
Sites 5

Hemophilia A

Key facts

Sponsor
Sanofi-Aventis Research & Development
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male
Therapeutic area
Diseases [C] - Hemic and Lymphatic Diseases [C15]
Trial duration
completed 24 Sep 2024
Decision date (initial)
2024-02-06
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

External identifiers

EU CT number
2022-502414-84-00
WHO UTN
U1111-1280-7227

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Hemophilia A

VersionLevelCodeTermSystem organ class
20.0 LLT 10060612 Hemophilia A 10010331

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Sanofi-Aventis Research & Development

Sponsor organisation
Sanofi-Aventis Research & Development
Address
1 Avenue Pierre Brossolette
City
Chilly Mazarin
Postcode
91380
Country
France

Scientific contact point

Organisation
Sanofi-Aventis Research & Development
Contact name
Clinical Sciences and Operations

Public contact point

Organisation
Sanofi-Aventis Research & Development
Contact name
Clinical Sciences and Operations

Locations

2 EU/EEA countries · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ended 3 2
Spain Ended 3 3
Rest of world
Taiwan, Mexico, United States
20

Investigational sites

Italy

2 sites · Ended
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Centro Emofilia e Trombosi, Via Francesco Sforza 28, 20122, Milan
Humanitas Research Hospital
U.O. Centro Trombosi e Malattie Emorragiche, Via Alessandro Manzoni 56, 20089, Rozzano

Spain

3 sites · Ended
Hospital Universitario La Paz
Haematology, Paseo Castellana 261, 28046, Madrid
Hospital Unviersitario Miguel Servet
Hemostasis and Thrombosis, Paseo De Isabel La Catolica 1-3, 50009, Zaragoza
Complexo Hospitalario Universitario A Coruna
Hemostasis and Thrombosis, Lugar Jubias De Arriba 84, 15006, A Coruna

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-10-06 Spain Acceptable with conditions
2024-02-05
2024-02-05